Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | How to dodge common pitfalls leading to prosecution in the pharma industryJoshua Holzer, Chief Compliance Counsel for Global Trade, Pfizer Inc, joins Pharma IQ to discuss common concerns of pharma companies when it comes to compliance regulatory investigations and strategies.
By: IQPC Pharma IQ: In this new heightened risk management environment, what are you seeing as the most common concerns of pharma companies when it comes to compliance regulatory investigations? J Holzer: Like in past years, potential corruption involving government officials as well as promotion and marketing activities really are popular areas of concern for pharma companies and companies worldwide in general. With the global nature of commerce though and increased compliance in global trade areas companies are increasingly looking at their level of compliance with global trade laws, and that’s import laws and export laws and certainly the sanctions and embargoes area with all of the changes after last year’s involvement of all the Middle East and Northern African countries in changes in political structure and restricted parties. And they’re putting resources towards dealing with those areas and they’re particularly important because they’re really complex and in-depth and the laws do change from country to country and they should be harmonised but they’re not necessarily that way. Pharma IQ: What do you feel are the most common pitfalls in the pharma industry that can lead to prosecution? Joshua Holzer will be speaking at the Information Governance & eDiscovery for Pharma, Biotech and Medical Devices conference, taking place 26 - 28 June 2012 in Munich, Germany. For information please visit: www.pharmaediscovery.com/ To download this interview in full and access the mp3, please click here - http://www.pharmaediscovery.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|